Malignant solid neoplasm, MSI-H or dMMR
Revision as of 18:42, 15 March 2018 by Warner-admin (talk | contribs) (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''" to "<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''-->")
4 regimens on this page
6 variants on this page
|
Note: this is a new type of page for HemOnc.org, as all other regimen pages (except for cancer of unknown primary) are tissue-specific. The initial drug with tissue-agnostic approval is for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Pembrolizumab monotherapy
Regimen
Study | Evidence |
---|---|
Le et al. 2016 (KEYNOTE-164) | Phase II |
Note: this is the FDA-approved pembrolizumab dose and schedule based on a pooled analysis of 5 non-randomized trials. This is one representative trial.
Immunotherapy
- Adults: Pembrolizumab (Keytruda) 200 mg IV once over 30 minutes on day 1
- Children: Pembrolizumab (Keytruda) 2 mg/kg (maximum dose 200 mg) IV once over 30 minutes on day 1
21-day cycle for up to 2 years
References
- Abstract: Dung T. Le, Takayuki Yoshino, Dirk Jäger, Thierry Andre, Johanna C. Bendell, Ruixue Wang... SoonMo Peter Kang, Minori Koshiji, Luis A. Diaz. KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. J Clin Oncol 2016 abstract TPS787 and abstract TPS3631; NCT02460198 at ClinicalTrials.gov